Literature DB >> 8675088

Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria.

A Macpherson1, U Y Khoo, I Forgacs, J Philpott-Howard, I Bjarnason.   

Abstract

In contrast with normal subjects where IgA is the main immunoglobulin in the intestine, patients with active inflammatory bowel disease (IBD) produce high concentrations of IgG from intestinal lymphocytes, but the antigens at which these antibodies are directed are unknown. To investigate the specificities of these antibodies mucosal immunoglobulins were isolated from washings taken at endoscopy from 21 control patients with irritable bowel syndrome, 10 control patients with intestinal inflammation due to infection or ischaemia, and 51 patients with IBD: 24 Crohn's disease (CD, 15 active, nine quiescent), 27 ulcerative colitis (UC, 20 active, seven inactive). Total mucosal IgG was much higher (p < 0.001) in active UC (median 512 micrograms/ml) and active CD (256 micrograms/ml) than in irritable bowel syndrome controls (1.43 micrograms/ml), but not significantly different from controls with non-IBD intestinal inflammation (224 micrograms/ml). Mucosal IgG bound to proteins of a range of non-pathogenic commensal faecal bacteria in active CD; this was higher than in UC (p < 0.01); and both were significantly greater than controls with non-IBD intestinal inflammation (CD p < 0.001, UC p < 0.01) or IBS (p < 0.001 CD and UC). This mucosal IgG binding was shown on western blots and by enzyme linked immunosorbent assay (ELISA) to be principally directed against the bacterial cytoplasmic rather than the membrane proteins. Total mucosal IgA concentrations did not differ between IBD and controls, but the IgA titres against faecal bacteria were lower in UC than controls (p < 0.01). These experiments show that there is an exaggerated mucosal immune response particularly in active CD but also in UC directed against cytoplasmic proteins of bacteria within the intestinal lumen; this implies that in relapse of IBD there is a breakdown of tolerance to the normal commensal flora of the gut.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675088      PMCID: PMC1383064          DOI: 10.1136/gut.38.3.365

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  41 in total

1.  Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn's disease of the colon.

Authors:  K Baklien; P Brandtzaeg
Journal:  Clin Exp Immunol       Date:  1975-11       Impact factor: 4.330

2.  Serum antibodies to Escherichia coli in subjects with ulcerative colitis.

Authors:  R J Heddle; D J Shearman
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

3.  Immunohistochemical changes in morphologically involved and uninvolved colonic mucosa of patients with idiopathic proctitis.

Authors:  K M Das; W F Erber; A Rubinstein
Journal:  J Clin Invest       Date:  1977-03       Impact factor: 14.808

4.  Enterobacterial common antigen-induced lymphocyte reactivity in inflammatory bowel disease.

Authors:  D M Bull; T F Ignaczak
Journal:  Gastroenterology       Date:  1973-01       Impact factor: 22.682

Review 5.  Transport across isolated bacterial cytoplasmic membranes.

Authors:  H R Kaback
Journal:  Biochim Biophys Acta       Date:  1972-08-04

6.  Secretory immunoglobulin deficiency in a family with inflammatory bowel disease.

Authors:  J F Engstrom; C Arvanitakis; A Sagawa; N I Abdou
Journal:  Gastroenterology       Date:  1978-04       Impact factor: 22.682

7.  Immunohistochemical characterization of local immunoglobulin formation in ulcerative colitis.

Authors:  P Brandtzaeg; K Baklien; O Fausa; P S Hoel
Journal:  Gastroenterology       Date:  1974-06       Impact factor: 22.682

8.  A technique for quantitative measurement of endotoxin in human plasma.

Authors:  R B Reinhold; J Fine
Journal:  Proc Soc Exp Biol Med       Date:  1971-05

9.  A study of peripheral leucocyte migration in agarose medium in inflammatory bowel disease.

Authors:  W Bartnik; E T Swarbrick; C Williams
Journal:  Gut       Date:  1974-04       Impact factor: 23.059

10.  Immunological studies in ulcerative colitis. VIII. Antibodies to colon antigen in patients with ulcerative colitis, Crohn's disease, and other diseases.

Authors:  H E Carlsson; R Lagercrantz; P Perlmann
Journal:  Scand J Gastroenterol       Date:  1977       Impact factor: 2.423

View more
  116 in total

Review 1.  Bacteria as the cause of ulcerative colitis.

Authors:  M Campieri; P Gionchetti
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

Review 2.  Diversity of antibody-mediated immunity at the mucosal barrier.

Authors:  J P Bouvet; V A Fischetti
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

3.  Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.

Authors:  N Borruel; M Carol; F Casellas; M Antolín; F de Lara; E Espín; J Naval; F Guarner; J R Malagelada
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 4.  Role of the innate immune system in the development of chronic colitis.

Authors:  Takanori Kanai; Ryoichi Ilyama; Takahiro Ishikura; Koji Uraushihara; Teruji Totsuka; Motomi Yamazaki; Tetsuya Nakamuma; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

Review 5.  Archaea and their potential role in human disease.

Authors:  Paul B Eckburg; Paul W Lepp; David A Relman
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

6.  Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease.

Authors:  S Dionne; S Laberge; C Deslandres; E G Seidman
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

7.  Prebiotic carbohydrates modify the mucosa associated microflora of the human large bowel.

Authors:  S J Langlands; M J Hopkins; N Coleman; J H Cummings
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

8.  B1a lymphocytes in the rectal mucosa of ulcerative colitis patients.

Authors:  Lino Polese; Riccardo Boetto; Giuseppe De Franchis; Imerio Angriman; Andrea Porzionato; Lorenzo Norberto; Giacomo Carlo Sturniolo; Veronica Macchi; Raffaele De Caro; Stefano Merigliano
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

9.  Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.

Authors:  E Furrie; S Macfarlane; J H Cummings; G T Macfarlane
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis.

Authors:  S Melgar; M M-W Yeung; A Bas; G Forsberg; O Suhr; A Oberg; S Hammarstrom; A Danielsson; M-L Hammarstrom
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.